Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dolichovespula maculata venom protein is a biologic extract derived from the venom of the bald-faced hornet (Dolichovespula maculata). It contains a complex mixture of biologically active compounds including enzymes, peptides, and proteins[2]. The primary clinical use is in allergy testing and diagnosis of hypersensitivity to vespid stings. The major allergenic component is antigen 5 (Dol m 5), a cysteine-rich 204-residue protein that serves as an important T-cell epitope in allergic responses[5]. Its mechanism involves eliciting an immune response in sensitized individuals for diagnostic purposes. This product is classified as an allergenic extract and used primarily for identifying patients at risk for severe allergic reactions to vespid stings[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dolichovespula maculata venom protein.